Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model

Continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) are main modalities for end stage renal disease (ESRD) patients, and those have been covered by National Health Insurance (NHI) scheme since 2014 in Indonesia. This study aims to update the cost-effectiveness model of CAPD versus...

Full description

Saved in:
Bibliographic Details
Published in:BMC research notes 2022-12, Vol.15 (1), p.359-359, Article 359
Main Authors: Putri, Septiara, Nugraha, Ryan R, Pujiyanti, Eka, Thabrany, Hasbullah, Hasnur, Hanifah, Istanti, Novita D, Evasari, Diah, Afiatin
Format: Article
Language:English
Subjects:
Chronic kidney failure
Continuous ambulatory peritoneal dialysis
Cost analysis
Cost benefit analysis
Cost-effectiveness
Dialysis
End stage renal disease
GDP
Gross Domestic Product
Hemodialysis
Hospitals
Humans
Indonesia
Interviews
Kidney diseases
Kidney Failure, Chronic - therapy
Laws, regulations and rules
Methods
Monte Carlo simulation
Palliative care
Patient outcomes
Patients
Peritoneal dialysis
Prevention
Quality of life
Questionnaires
Research Note
Risk factors
Sensitivity analysis
Survival analysis
Technology application
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) are main modalities for end stage renal disease (ESRD) patients, and those have been covered by National Health Insurance (NHI) scheme since 2014 in Indonesia. This study aims to update the cost-effectiveness model of CAPD versus HD in Indonesia setting. Compared to HD, CAPD provides good value for money among ESRD patients in Indonesia. Using societal perspective, the total costs were IDR 1,348,612,118 (USD 95,504) and IDR 1,368,447,750 (USD 96,908), for CAPD and HD, respectively. The QALY was slightly different between two modalities, 4.79 for CAPD versus 4.22 for HD. The incremental cost-effectiveness ratio (ICER) yields savings of IDR 34,723,527/QALY (USD 2460).
ISSN:1756-0500
1756-0500
DOI:10.1186/s13104-022-06252-4